| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.7 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.018 | 0.7 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |